Overview Financials News + Filings Key Docs Charts Ownership Insiders
|
Mirati Therapeutics, Inc. (MRTX)
|
|
Common Size Income Statement |
|
|
|
|
Annual | Quarterly | TTM |
|
In millions, except per share items | Dec-31-22 | Dec-31-21 | Dec-31-20 | Dec-31-19 | Dec-31-18 | Dec-31-17 | Dec-31-16 | Dec-31-15 |
| 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K |
Revenues | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | | | |
Cost of goods sold | 4.8% | 0.0% | 0.0% | 0.0% | 0.0% | | | |
Gross profit | 95.2% | 100.0% | 100.0% | 100.0% | 100.0% | | | |
Selling, general and administrative | 1928.3% | 189.6% | 622.6% | | | | | |
Research and development | 4274.9% | 705.5% | 2234.3% | 5483.2% | 726.2% | | | |
General and administrative | | | | 1276.6% | 167.7% | | | |
EBITDA | -6084.4% | -792.6% | -2752.1% | -6652.3% | -792.6% | | | |
Depreciation | 23.6% | 2.5% | 4.8% | 7.5% | 1.4% | | | |
EBIT | -6108.0% | -795.1% | -2756.9% | -6659.8% | -794.0% | | | |
Pre-tax income | -5953.4% | -802.4% | -2671.6% | -6394.5% | -761.4% | | | |
Income taxes | 4.1% | 4.6% | 0.0% | 0.0% | 0.0% | | | |
Net income | -5957.4% | -807.0% | -2671.6% | -6394.5% | -761.4% | | | |
|